Anzeige
Erschienen in:
22.11.2016 | Erratum
Erratum to: Prognostic Relevance of the Timing of Initiating and the Completion of Adjuvant Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma
Erschienen in: World Journal of Surgery | Ausgabe 2/2017
Einloggen, um Zugang zu erhaltenExcerpt
In the original article, there are errors in Fig. 2 and Table 4. Following are the corrected Fig. 2 and Table 4.
Fig. 2
Comparison of survival curves between the complete and incomplete adjuvant therapy groups: a overall survival, b disease-free survival
Table 4
Univariate and multivariable analysis of prognostic factors for overall survival in all patients
|
Variables
|
Univariate analysis
|
Multivariable analysis
|
||||
|---|---|---|---|---|---|---|
|
Subgroup (n)
|
Median OS (months)
|
p values
|
HR
|
95% CI
|
p values
|
|
|
Age
|
<70 (246)
|
36.5
|
0.888
|
|||
|
≥70 (65)
|
34.0
|
|||||
|
Sex
|
Male (192)
|
33.7
|
0.059
|
1.167
|
0.783–1.738
|
0.448
|
|
Female (119)
|
38.0
|
|||||
|
BMI
|
<25 kg/m2 (242)
|
33.7
|
0.226
|
|||
|
≥25 kg/m2 (69)
|
42.4
|
|||||
|
CA 19-9
|
<37 IU/L (90)
|
42.9
|
0.082
|
1.498
|
0.989–2.263
|
0.056
|
|
≥37 IU/L (179)
|
35.8
|
|||||
|
Tumor site
|
Head (216)
|
33.0
|
0.004
|
1.210
|
0.648–2.258
|
0.549
|
|
Body/tail (95)
|
61.0
|
|||||
|
Intraoperative transfusion
|
Yes (45)
|
32.4
|
0.312
|
|||
|
No (266)
|
37.5
|
|||||
|
Angiolymphatic invasion
|
Yes (112)
|
28.7
|
<0.001
|
2.250
|
1.533–3.303
|
<0.001
|
|
No (199)
|
61.0
|
|||||
|
Microscopic venous invasion
|
Yes (117)
|
34.0
|
0.118
|
|||
|
No (194)
|
48.4
|
|||||
|
Perineural invasion
|
Yes (190)
|
33.6
|
0.001
|
1.350
|
0.876–2.080
|
0.174
|
|
No (121)
|
61.0
|
|||||
|
Tumor size
|
<3 cm (135)
|
37.0
|
0.091
|
1.205
|
0.813–1.786
|
0.352
|
|
≥3 cm (176)
|
33.7
|
|||||
|
T stage
|
T2 (7)
|
165
|
0.270
|
|||
|
T3 (293)
|
28
|
|||||
|
N stage
|
N0 (147)
|
48.2
|
0.010
|
1.298
|
0.856–1.966
|
0.219
|
|
N1 (164)
|
29.9
|
|||||
|
R1 resection margin
|
Yes (28)
|
36.0
|
0.136
|
|||
|
No (283)
|
37.0
|
|||||
|
Completion of adjuvant therapy
|
Yes (179)
|
42.4
|
0.001
|
1.850
|
1.266–2.702
|
0.001
|
|
No (132)
|
28.7
|
|||||
|
Time to the initiation of adjuvant therapy
|
≤6 weeks (147)
|
33.7
|
0.539
|
|||
|
>6 weeks (164)
|
38.0
|
|||||
|
CCRT
|
Yes (242)
|
36.0
|
0.326
|
|||
|
No (69)
|
36.5
|
|||||
|
Chemotherapy regimen
|
5-FU–based (188)
|
36.5
|
0.307
|
|||
|
Gemcitabine-based (123)
|
35.8
|
|||||
|
Postoperative complications
|
Yes (103)
|
46.2
|
0.150
|
|||
|
No (208)
|
30.9
|
|||||
|
Adverse events of adjuvant therapy (CTC grade ≥ 3)
|
Yes (70)
|
37.0
|
0.744
|
|||
|
No (239)
|
33.7
|
|||||
× ![]()
…